A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken with Rosuvastatin

Study identifier:15994

ClinicalTrials.gov identifier:NCT03019549

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Lanabecestat, Rosuvastatin

Sex

All

Actual Enrollment

42

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 12 Jan 2017
Primary Completion Date: 22 May 2017
Study Completion Date: 22 May 2017

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria